Biomarker · Gene alteration
KRAS G12C
KRAS codon 12 point mutation p.G12C detected by sequencing or PCR in tumor tissue or plasma; used as a predictive marker for KRAS G12C inhibitors in non-small cell lung and colorectal cancer.
CI-BIO-00000015KRASgraph →NCIt C98365
Also calledp.G12C · KRAS G12C-mutated · c.34G>T
Derived
Associated cancers (6)
Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.
| Cancer | Items | Predictive | Prognostic | Diagnostic | Levels A / B / C / D / E |
|---|---|---|---|---|---|
| Malignant Colorectal Neoplasm | 7 | 7 | — | — | 2 / 2 / 1 / 2 / 0 |
| Lung Non-Small Cell Carcinoma | 4 | 3 | 1 | — | 1 / 3 / 0 / 0 / 0 |
| Multiple Myeloma | 3 | 3 | — | — | 0 / 0 / 0 / 3 / 0 |
| Malignant Lung Neoplasm | 2 | 1 | — | 1 | 0 / 2 / 0 / 0 / 0 |
| Malignant Neoplasm |
Derived
Drugs with predictive evidence (15)
Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.
| Drug | CIViC items | Sensitivity | Resistance | Best level | Edges (S / R) | Cancer context |
|---|---|---|---|---|---|---|
| MelphalanSmall Molecule | 3 | — | 3 | D | 0 / 3 | Multiple Myeloma |
| AdagrasibSmall Molecule | 2 | 2 | — | A | 2 / 0 | Malignant Colorectal Neoplasm, Solid Neoplasm |
| Cetuximab |
Curated evidence
Predictive evidence items (16)
ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37611121
- Run
- ING-CIVIC-20260908-000001
Regulatory
Approvals mentioning the linked drugs (168)
Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
Clinical trials
Active trials (279)
Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 157 recruiting · 64 active phase 3 · 1,595 in any status. Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 |
Literature
Linked publications (17)
Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)